Abstract
SummaryCellular senescence is a driver of many age-related pathologies. There is an active search for pharmaceuticals termed senolytics that can mitigate or remove senescent cells in vivo by targeting genes that promote the survival of senescent cells. We utilized single-cell RNA sequencing to identify CRYAB as a robust senescence-induced gene and potential target for senolysis. Using chemical inhibitor screening for CRYAB disruption, we identified 25-hydroxycholesterol (25HC), an endogenous metabolite of cholesterol biosynthesis, as a potent senolytic. We then validated 25HC as a senolytic in mouse and human cells in culture and in vivo in mouse skeletal muscle. Thus, 25HC represents a potential class of senolytics, which may be useful in combating diseases or physiologies in which cellular senescence is a key driver.
Highlights
Cellular senescence causes proliferative cells to undergo an essentially permanent cell-cycle arrest upon encountering stressful stimuli such as genotoxic chemotherapy, radiation, or telomere shortening (Bernadotte et al, 2016; Demaria et al, 2017; Limbad et al, 2020)
There is an active search for pharmaceuticals termed senolytics that can mitigate or remove senescent cells in vivo by targeting genes that promote the survival of senescent cells
Using chemical inhibitor screening for CRYAB disruption, we identified 25-hydroxycholesterol (25HC), an endogenous metabolite of cholesterol biosynthesis, as a potent senolytic
Summary
Cellular senescence causes proliferative cells to undergo an essentially permanent cell-cycle arrest upon encountering stressful stimuli such as genotoxic chemotherapy, radiation, or telomere shortening (Bernadotte et al, 2016; Demaria et al, 2017; Limbad et al, 2020). There is an active search for drugs that can kill senescent cells (senolytics) (van Deursen, 2019). This class of drugs improves health span in multiple contexts of aging, and has potential to mitigate many age related diseases (Chang et al, 2016; Fuhrmann-Stroissnigg et al, 2017; Kim and Kim, 2019; Kirkland and Tchkonia, 2017; Wissler Gerdes et al, 2020; Xu et al, 2018). The potential benefits of ABT as a senolytic were studied after skeletal muscle injury (Chiche et al, 2017), but no benefits were reported in aging skeletal muscle
Full Text
Topics from this Paper
Full Text PDF PubMed Scopus
PubMed Scopus
Fibro-adipogenic Progenitors
Google Scholar
Single-cell Sequencing
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
iScience
Jan 1, 2023
Molecular Cell
May 1, 2019
Journal of Investigative Dermatology
Jul 1, 2015
Cell Metabolism
Nov 1, 2021
Stem Cell Reports
Feb 1, 2018
Cell Reports
May 1, 2022
The American Journal of Pathology
Oct 1, 2015
Journal of Investigative Dermatology
Feb 1, 2021
The Lancet Healthy Longevity
Jan 1, 2022
Trends in Molecular Medicine
Oct 1, 2012
Cell Stem Cell
Jun 1, 2021
Journal of Biological Chemistry
Apr 1, 2017
Journal of Biological Chemistry
Jun 1, 2009
Cell Reports
Aug 1, 2020
Stem Cell Reports
Mar 1, 2018
iScience
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023
iScience
Dec 1, 2023